- call +1-201-465-4211
- email sales@mrinsights.biz
Necrotizing fasciitis (NF), commonly known as flesh-eating disease, is an infection that results in the death of the body's soft tissue. It is a severe disease of sudden onset that spreads rapidly. Symptoms include red or purple skin in the affected area, severe pain, fever, and vomiting. The most commonly affected areas are the limbs and perineum.
Scope of the Report:
This report studies the Necrotizing Fasciitis market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Necrotizing Fasciitis market by product type and applications/end industries.
Necrotizing fasciitis affects 0.4 to 1.0 person per 100,000 per year. Both sexes are affected equally. It becomes more common among older people and is very rare in children. Surgical debridement (cutting away affected tissue) is the mainstay of treatment for necrotizing fasciitis. Early medical treatment is often presumptive; thus, antibiotics should be started as soon as this condition is suspected. Cultures are taken to determine appropriate antibiotic coverage, and antibiotics may be changed when culture results are obtained. Besides blood pressure control and hydration, support should be initiated for those with unstable vital signs and low urine output.
The global Necrotizing Fasciitis market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Necrotizing Fasciitis.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Merck
Wockhardt
Atox Bio
Teva Pharmaceutical Industries
Basilea Pharmaceutica
Melinta Therapeutics
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Type I
Type II
Type III
Market Segment by Applications, can be divided into
Hospital & Clinics
Surgical Centers
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Necrotizing Fasciitis Market Overview
1.1 Product Overview and Scope of Necrotizing Fasciitis
1.2 Classification of Necrotizing Fasciitis by Types
1.2.1 Global Necrotizing Fasciitis Revenue Comparison by Types (2017-2023)
1.2.2 Global Necrotizing Fasciitis Revenue Market Share by Types in 2017
1.2.3 Type I
1.2.4 Type II
1.2.5 Type III
1.3 Global Necrotizing Fasciitis Market by Application
1.3.1 Global Necrotizing Fasciitis Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital & Clinics
1.3.3 Surgical Centers
1.4 Global Necrotizing Fasciitis Market by Regions
1.4.1 Global Necrotizing Fasciitis Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Necrotizing Fasciitis Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Necrotizing Fasciitis Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Necrotizing Fasciitis Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Necrotizing Fasciitis Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Necrotizing Fasciitis Status and Prospect (2013-2023)
1.5 Global Market Size of Necrotizing Fasciitis (2013-2023)
2 Manufacturers Profiles
2.1 Merck
2.1.1 Business Overview
2.1.2 Necrotizing Fasciitis Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Merck Necrotizing Fasciitis Revenue, Gross Margin and Market Share (2016-2017)
2.2 Wockhardt
2.2.1 Business Overview
2.2.2 Necrotizing Fasciitis Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Wockhardt Necrotizing Fasciitis Revenue, Gross Margin and Market Share (2016-2017)
2.3 Atox Bio
2.3.1 Business Overview
2.3.2 Necrotizing Fasciitis Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Atox Bio Necrotizing Fasciitis Revenue, Gross Margin and Market Share (2016-2017)
2.4 Teva Pharmaceutical Industries
2.4.1 Business Overview
2.4.2 Necrotizing Fasciitis Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Teva Pharmaceutical Industries Necrotizing Fasciitis Revenue, Gross Margin and Market Share (2016-2017)
2.5 Basilea Pharmaceutica
2.5.1 Business Overview
2.5.2 Necrotizing Fasciitis Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Basilea Pharmaceutica Necrotizing Fasciitis Revenue, Gross Margin and Market Share (2016-2017)
2.6 Melinta Therapeutics
2.6.1 Business Overview
2.6.2 Necrotizing Fasciitis Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Melinta Therapeutics Necrotizing Fasciitis Revenue, Gross Margin and Market Share (2016-2017)
3 Global Necrotizing Fasciitis Market Competition, by Players
3.1 Global Necrotizing Fasciitis Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Necrotizing Fasciitis Players Market Share
3.2.2 Top 10 Necrotizing Fasciitis Players Market Share
3.3 Market Competition Trend
4 Global Necrotizing Fasciitis Market Size by Regions
4.1 Global Necrotizing Fasciitis Revenue and Market Share by Regions
4.2 North America Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
4.3 Europe Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
4.5 South America Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
5 North America Necrotizing Fasciitis Revenue by Countries
5.1 North America Necrotizing Fasciitis Revenue by Countries (2013-2018)
5.2 USA Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
5.3 Canada Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
5.4 Mexico Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
6 Europe Necrotizing Fasciitis Revenue by Countries
6.1 Europe Necrotizing Fasciitis Revenue by Countries (2013-2018)
6.2 Germany Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
6.3 UK Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
6.4 France Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
6.5 Russia Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
6.6 Italy Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Necrotizing Fasciitis Revenue by Countries
7.1 Asia-Pacific Necrotizing Fasciitis Revenue by Countries (2013-2018)
7.2 China Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
7.3 Japan Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
7.4 Korea Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
7.5 India Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
8 South America Necrotizing Fasciitis Revenue by Countries
8.1 South America Necrotizing Fasciitis Revenue by Countries (2013-2018)
8.2 Brazil Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
8.3 Argentina Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
8.4 Colombia Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Necrotizing Fasciitis by Countries
9.1 Middle East and Africa Necrotizing Fasciitis Revenue by Countries (2013-2018)
9.2 Saudi Arabia Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
9.3 UAE Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
9.4 Egypt Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
9.5 Nigeria Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
9.6 South Africa Necrotizing Fasciitis Revenue and Growth Rate (2013-2018)
10 Global Necrotizing Fasciitis Market Segment by Type
10.1 Global Necrotizing Fasciitis Revenue and Market Share by Type (2013-2018)
10.2 Global Necrotizing Fasciitis Market Forecast by Type (2018-2023)
10.3 Type I Revenue Growth Rate (2013-2023)
10.4 Type II Revenue Growth Rate (2013-2023)
10.5 Type III Revenue Growth Rate (2013-2023)
11 Global Necrotizing Fasciitis Market Segment by Application
11.1 Global Necrotizing Fasciitis Revenue Market Share by Application (2013-2018)
11.2 Necrotizing Fasciitis Market Forecast by Application (2018-2023)
11.3 Hospital & Clinics Revenue Growth (2013-2018)
11.4 Surgical Centers Revenue Growth (2013-2018)
12 Global Necrotizing Fasciitis Market Size Forecast (2018-2023)
12.1 Global Necrotizing Fasciitis Market Size Forecast (2018-2023)
12.2 Global Necrotizing Fasciitis Market Forecast by Regions (2018-2023)
12.3 North America Necrotizing Fasciitis Revenue Market Forecast (2018-2023)
12.4 Europe Necrotizing Fasciitis Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Necrotizing Fasciitis Revenue Market Forecast (2018-2023)
12.6 South America Necrotizing Fasciitis Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Necrotizing Fasciitis Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Necrotizing Fasciitis Picture
Table Product Specifications of Necrotizing Fasciitis
Table Global Necrotizing Fasciitis and Revenue (Million USD) Market Split by Prod
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
